The increase in plasma BAFF during anti-CD20 therapy has been documented in several reports about Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Sjögren syndrome and, recently, in MS too [57,60,61,62,63]. This evidence concerns the gene TNFSF13B and rheumatoid arthritis.